Algonomics wins $1.2 million research funding from Flemish Government

Under the research program, Algonomics will collaborate with the research groups of Soren Buus (University of Copenhagen, Denmark) and Roberto Mallone (Inserm, France).

This two year funding will drive further development of Algonomics’s Epibase platform for predictive immunogenicity of biotherapeutics. Epibase is broadly used in the biopharma industry to estimate the relative risk to observe an immune response against protein therapeutics.

This research project is specifically geared towards a better understanding of the interaction between the T-cell receptor and major histocompatibility complex peptide-complexes, said Algonomics.

Philippe Stas, CEO of Algonomics, said: “This collaboration with top-notch research groups in the field of T-cell biology and immunology, allows our team to exchange know-how and valuable insights in the mechanisms driving immune responses and immunogenicity.”